Get the facts about safety and side effects
Patient portrayal.
The safety of the RHAPSIDO® (remibrutinib) pill was evaluated in the largest clinical study of an oral treatment for chronic hives with no known external triggers†
†Based on completed trials for CSU as of September 2025.
The most common side effects seen in clinical trials (RHAPSIDO [n=606]; placebo [n=306]):
Nasopharyngitis (nasal congestion, sore throat, and runny nose)
11% of those who took RHAPSIDO and 9% who took placebo
Bleeding
9% of those who took RHAPSIDO and 2% who took placebo; of the 9%, the most common types of bleeding were tiny red spots under the skin (4%) and bruising (2%)
Headache
7% of those who took RHAPSIDO and 6% who took placebo
Nausea
3% of those who took RHAPSIDO and 2% who took placebo
Abdominal Pain
3% of those who took RHAPSIDO and 2% who took placebo
These are not all of the possible side effects of RHAPSIDO. View the full Prescribing Information to learn more.
Over 900 people were included in the clinical trials for RHAPSIDO.
